Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shinji Takeuchi

Showing results (41-50 of 116) with videos related to

Pageof 12
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 18, 2012
Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesisHitomi Koizumi, Tadaaki Yamada, Shinji Takeuchi, et al.
Cancer Medicine|November 23, 2022
MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangementsYohei Takumi, Sachiko Arai, Chiaki Suzuki, et al.
Cancer Science|May 6, 2017
Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathwayHirokazu Taniguchi, Tadaaki Yamada, Shinji Takeuchi, et al.
International Journal of Clinical Oncology|July 6, 2010
Metastatic renal cell carcinoma complicated with diffuse alveolar hemorrhage: a rare adverse effect of sunitinibTadaaki Yamada, Koushiro Ohtsubo, Kouji Izumi, et al.
Oncotarget|December 31, 2015
High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cellsShigeki Nanjo, Hiromichi Ebi, Sachiko Arai, et al.
BMC Cancer|February 26, 2020
Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case reportYuta Adachi, Naohiro Yanagimura, Chiaki Suzuki, et al.
Cancer Science|September 8, 2011
Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cellsTadaaki Yamada, Hideaki Bando, Shinji Takeuchi, et al.
Cancer Science|October 27, 2016
Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitorsHirokazu Taniguchi, Shinji Takeuchi, Koji Fukuda, et al.
Cancer Science|October 15, 2013
Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancerLu Zhao, Kazuo Yasumoto, Atsuhiro Kawashima, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2011
Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancerIvan S Donev, Wei Wang, Tadaaki Yamada, et al.
Pageof 12

Showing results (41-50 of 116) with videos related to

Sort By:
Pageof 12
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 18, 2012
Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesisHitomi Koizumi, Tadaaki Yamada, Shinji Takeuchi, et al.
Cancer Medicine|November 23, 2022
MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangementsYohei Takumi, Sachiko Arai, Chiaki Suzuki, et al.
Cancer Science|May 6, 2017
Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathwayHirokazu Taniguchi, Tadaaki Yamada, Shinji Takeuchi, et al.
International Journal of Clinical Oncology|July 6, 2010
Metastatic renal cell carcinoma complicated with diffuse alveolar hemorrhage: a rare adverse effect of sunitinibTadaaki Yamada, Koushiro Ohtsubo, Kouji Izumi, et al.
Oncotarget|December 31, 2015
High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cellsShigeki Nanjo, Hiromichi Ebi, Sachiko Arai, et al.
BMC Cancer|February 26, 2020
Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case reportYuta Adachi, Naohiro Yanagimura, Chiaki Suzuki, et al.
Cancer Science|September 8, 2011
Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cellsTadaaki Yamada, Hideaki Bando, Shinji Takeuchi, et al.
Cancer Science|October 27, 2016
Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitorsHirokazu Taniguchi, Shinji Takeuchi, Koji Fukuda, et al.
Cancer Science|October 15, 2013
Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancerLu Zhao, Kazuo Yasumoto, Atsuhiro Kawashima, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2011
Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancerIvan S Donev, Wei Wang, Tadaaki Yamada, et al.
Pageof 12